Gossamer Bio (GOSS) Total Current Liabilities (2018 - 2026)

Gossamer Bio has reported Total Current Liabilities for 9 years, with the latest figure at $137.8 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 157.09% year-over-year to $137.8 million in Q2 2026; TTM through Jun 2026 was $137.8 million, a 157.09% increase from a year earlier, with the FY2025 full-year figure at $63.4 million, up 40.94% from the prior year.
• Total Current Liabilities was $137.8 million for Q2 2026 at Gossamer Bio, up from $56.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $137.8 million in Q2 2026, with the low at $34.6 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $53.0 million, with a median of $48.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities decreased 19.62% in 2023, then jumped 157.09% in 2026.
• Over 5 years, Total Current Liabilities stood at $49.2 million in 2022, then climbed by 4.81% to $51.6 million in 2023, then retreated by 12.77% to $45.0 million in 2024, then jumped by 40.94% to $63.4 million in 2025, then soared by 117.2% to $137.8 million in 2026.
• The last three Total Current Liabilities figures came in at $137.8 million (Q2 2026), $56.5 million (Q1 2026), and $63.4 million (Q4 2025), per Business Quant data.